EP2017263A1 — Heteroarylamide lower carboxylic acid derivative

USPTO Abstract

To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH 2 -; R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G 1 -, (2) -G 2 -N(R 2 ) -G 3 -, and (3) a group represented by formula 2, wherein each of Z 1 and Z 2 represents a hydrogen atom or a C 1 -C 6 alkyl group, Z 3 represents a hydrogen or the like, Q represents -CH 2 -O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.